Dr. Adele Diamond speaks to the power of executive function and its impact on student learning in this TEDxWestVancouverEd talk.
- Home
- About
- COVID-19
- Research
- Clinics
- DMCBH Membership
- News & Events
- Donate
- Contact
Newsroom
For media enquiries or more information about research at the Djavad Mowafaghian Centre for Brain Health, please contact Vanessa Hrvatin, Communications Coordinator.
- Email: vanessa.hrvatin@ubc.ca
- Phone: 604-827-4295
To keep in touch with the Centre and up-to-date on our research, follow us on Twitter or subscribe to Brain Matters, our monthly e-newsletter.
Collaborative International Research in Clinical and Longitudinal Experience for NMO Studies
In North America, Neuromyelitis Optica (NMO) affects four in 100,000 people, and can cause loss of vision in one or both eyes (optic neuritis) and numbness and weakness in the arms and legs (transverse myelitis). It is an unpredictable and chronic illness that is often confused with Multiple Sclerosis, but NMO is a distinct disease requiring different treatment.
Young athletes who experience concussions may need to wait longer than currently recommended before getting ‘back in the game’ because of the unique brain developmental stage of adolescence, according to new research. The study, published in the Journal of Neurotrauma, shows that current adult-based standards for assessing the effects of concussions and length of time to recovery may be inadequate for adolescents.
Interferon beta (IFN-β) is a disease-modifying drug used to reduce the risk of a future relapse (attacks) in people with multiple sclerosis (MS) by modulating the immune system. And while IFN-β is considered safe, it does hold a small possibility of side effects, including liver injury. While 30 to 60 per cent of individuals with MS treated with IFN-β will experience elevations in their liver enzyme test results, these elevations are often transient and disappear even with continued IFN-β treatment.
Neuromyelitis Optica (NMO) Information Day
Oct 23, 2014
+
The third annual Neuromyelitis Optica (NMO) Information Day will be held at the Djavad Mowafaghian Centre for Brain Health (DMCBH) on November 1, from 10:00 a.m. to 4:00 p.m.
Dr. Haakon Nygaard comes to the Djavad Mowafaghian Centre for Brain Health (DMCBH) from Yale University, where he completed his internship in Internal Medicine, Residency in Neurology, and a PhD in Investigative Medicine under the mentorship of Dr. Stephen Strittmatter. He joined the Yale faculty as an Assistant Professor in Neurology, and during this time he co-founded the first Alzheimer’s clinic at Yale, and was the founding director of the Yale Behavioral Neurology and Neuropsychiatry fellowship program. Dr.
For the better part of a century, the neurotransmitter dopamine has been understood as a key player in the brain’s reward-related processing. Djavad Mowafaghian Centre for Brain Health and Vancouver Coastal Health Research Institute researcher Dr. Stan Floresco has discovered more precisely that bursts and dips of dopamine activity in the brain guide the level of risk taken when making a choice.
Researcher profile: Dr. Dan Marigold
Oct 16, 2014
+
In order to pursue discovery and improve the mobility of people with eye disease and other neurological conditions, Dr. Marigold’s research combines basic science with clinically relevant scenarios.
Molecular geneticist Dr. Carles Vilarino-Guell has played an important role in the identification of the genes that carry mutations responsible for the onset of neurological diseases such as Parkinson’s and Multiple Sclerosis.
Pictured:The dendrites of one neuron (red), and microglial cells (green).
Researchers in Dr. Brian MacVicar’s lab recently established a novel communication pathway between neurons and microglia, the brain’s immune cells.
